MLL/KMT2A anticorps (AA 3751-3968)

N° du produit ABIN969286

Détail du produit anti-MLL/KMT2A anticorps

Antigène: MLL/KMT2A (MLL) (Myeloid/lymphoid Or Mixed-Lineage Leukemia (MLL))

Épitope: AA 3751-3968

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp MLL/KMT2A est non-conjugé

Application: Western Blotting (WB), ELISA, Immunohistochemistry (IHC)

Purification: purified

Immunogène: Purified recombinant fragment of MLL (aa3751-3968) expressed in E. coli.

Clone: 10F8D7

Isotype: IgG1

Information d'application

Indications d'application: ELISA: 1:10000, WB: 1:500 - 1:2000, IHC: 1:200 - 1:1000

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Ascitic fluid containing 0.03 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C/-20 °C

Stockage commentaire: 4°C, -20°C for long term storage

Références pour anticorps anti-MLL/KMT2A (ABIN969286)

Nigro, Sainati, Leszl, Mirabile, Spinelli, Consarino, Di Cataldo, Magro, Felix, Basso: "Acute differentiated dendritic cell leukemia: a variant form of pediatric acute myeloid leukemia with MLL translocation." dans: Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, Vol. 21, Issue 2, pp. 360-2, (2007) (PubMed).

Partida-Pérez, Domínguez, Sánchez-Corona, Castañeda-Cisneros, García-González, López-Cardona, Rivera: "Constitutional duplication 11q23 de novo involving the MLL gene." dans: Genetic counseling (Geneva, Switzerland), Vol. 17, Issue 2, pp. 155-9, (2006) (PubMed).

Kadkol, Bruno, Oh, Schmidt, Lindgren: "MLL-SEPT6 fusion transcript with a novel sequence in an infant with acute myeloid leukemia." dans: Cancer genetics and cytogenetics, Vol. 168, Issue 2, pp. 162-7, (2006) (PubMed).

Détails sur MLL/KMT2A

Antigène: MLL/KMT2A (MLL) (Myeloid/lymphoid Or Mixed-Lineage Leukemia (MLL))

Autre désignation: MLL (MLL Produits)

Synonymes: anticorps ALL-1, anticorps CXXC7, anticorps HRX, anticorps HTRX1, anticorps MLL, anticorps MLL/GAS7, anticorps MLL1A, anticorps TET1-MLL, anticorps TRX1, anticorps WDSTS, anticorps 6430520K01, anticorps All1, anticorps Cxxc7, anticorps Mll, anticorps Mll1, anticorps mKIAA4050, anticorps lysine methyltransferase 2A, anticorps lysine (K)-specific methyltransferase 2A, anticorps KMT2A, anticorps Kmt2a

Sujet:

Description: Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila). Eukaryotic RNA polymerase II mediates the synthesis of mature and functional messenger RNA. This is a multistep process, called the transcription cycle,that includes five stages: preinitiation, promoter, clearance, elongation and termination. Elongation is thought to be a critical stage for the regulation of gene expression. ELL (11-19 lysine-rich leukemia protein, also designated MEN) functions as an RNA polymerase II elongation factor that increases the rateof transcription by suppressing transient pausing by RNA polymerase II. Also, ELL is thought to regulate cellular proliferation. ELL is abundantly expressed in peripheral blood leukocytes, skeletal muscle, placenta and testis, and has lower expression in spleen, thymus, heart, brain, lung, kidney, liver and ovary.The gene encoding human ELL, which maps to chromosome 19p13.1, is one of several genes which undergo translocation with the MLL gene on chromo-some 11q23 in acute myeloid leukemia. MLL (myeloid/lymphoid leukemia,also designated ALL-1 and HRX) is a 430 kDa protein that regulates embryonal and hematopoietic development.

Aliases: MLL

ID gène: 4297

HGNC: 4297

Pathways: L'effet Warburg